Patrys is the first known company to develop technology that enables it to systematically capture, identify and produce commercial quantities of the most potent anti-cancer natural human antibodies, which allows Patrys to develop these antibodies as treatments for cancer.

Patrys’ proprietary technologies cover antibody capture, screening, target discovery and large scale production.

Over 45 peer reviewed articles have been published by Patrys researchers covering the above discovery and development technologies and the associated antibodies and targets.

A brief description of these technologies set out below:

Antibody Capture and Screening

The first step in Patrys’ approach involves the isolation from human donors of individual B-cells that produce antibodies that attack cancer tissues but ignore normal tissues.

Antibodies are then selected for further development based on their anti-cancer activity as determined through an extensive array of in vitro and in vivo experiments.

Target Discovery

The classical approach by antibody companies is to raise antibodies to known targets on the surface of cancer cells (i.e., target first, antibody second).  In most cases, the companies taking this approach go after targets that are either in the public domain or owned by other parties.  This in turn prevents those antibody companies from blocking others from developing second generation antibodies to the respective cancer disease targets.

In stark contrast, Patrys has taken the reverse approach of first identifying lead anti-cancer antibodies based on their ability to kill cancer and ignore healthy tissue, then using the lead antibodies to identify the target on cancer cells against which the antibodies are directed, and through which the antibodies kill cancer cells.

To date, Patrys' approach has led to the discovery of six new cancer-specific disease targets (on cancer but not healthy cells screened), which in turn provides therapeutic and safety benefits.  Because the targets discovered are novel, Patrys can file patent applications on such targets.  The commercial implication of the Patrys approach to targets is significant as there are no known competitors developing products against the disease targets for Patrys’ lead products.

Large Scale Recombinant Production

Once a lead product is nominated as a clinical candidate, Patrys transfers/transfects the antibody's genes from the respective human B1 cell into the FDA/regulatory compliant, high producing human recombinant cell line PER.C6®. Patrys has secured a broad license for PER.C6® from its owner, Crucell N.V.

To date, Patrys has moved lead products PAT-SM6, PAT-LM1 and PAT-CM1 into PER.C6® production cell lines, with great success in terms of average yields and stability. View Scientific Publications.
PAT-SC1 and PAT-PA1 are currently being converted to the PER.C6® human antibody production cell line.

Production Yields achieved with PER.C6® Technology

Antibody production slide is a third party data point taken from Crucell N.V ( view here)

The PERC.6® cell line has excellent safety profile, scalability and productivity under serum-free culture conditions.  PERC.6® is recognised by the FDA and enhances any IND filing and approval process.  A number of lead candidates have already been optimised in human cell line PERC.6® at production rates sufficient to support clinical development.  This human cell line is widely recognised by big pharma with over 45 licences issued to date.